세계의 결핵 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 질환 유형별, 치료법별, 투여 경로별, 제형별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Disease Type, By Therapy, By Route of Administration, By Dosage Form, By Distribution Channel, By Region & Competition, 2020-2030F
세계의 결핵 치료제 시장은 2024년에 21억 8,000만 달러로 평가되었고, 2030년에는 29억 4,000만 달러에 이를것으로 예측되며, CAGR 5.05%로 성장할 것으로 전망됩니다.
감염병 치료 분야에서 중요한 부문으로 자리매김한 이 시장은 특히 약제 내성 결핵의 발생률 증가로 인해 전 세계적으로 지속적인 수요의 혜택을 받고 있습니다. 결핵 치료제는 역사적으로 낮은 수익률에도 불구하고 공중 보건적 가치와 장기적인 상업적 잠재력이 큰 분야입니다. 각국 정부, 보건기관, 제약회사는 전 세계적으로 꾸준히 증가하는 결핵 환자 수와 기부자 및 공공 기관의 막대한 자금 지원에 힘입어 혁신적인 결핵 치료제 개발에 점점 더 우선순위를 두고 있습니다. 특히 2차 치료제를 중심으로 차세대 신약 개발이 증가함에 따라 비용 효율성의 균형을 맞추고 규제 환경을 탐색하며 전략적 협업을 구축할 수 있는 기업은 지속 가능한 경쟁 우위를 확보할 수 있는 유리한 위치에 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모(2024년) |
21억 8,000만 달러 |
| 시장 규모(2030년) |
29억 4,000만 달러 |
| CAGR(2025-2030년) |
5.05% |
| 급성장 부문 |
1차 치료제 |
| 최대 시장 |
중동 및 아프리카 |
시장 성장 촉진요인
높은 글로벌 결핵 부담
주요 시장 과제
신약 개발을 위한 불충분한 자금과 제한된 상업적 인센티브
주요 시장 동향
더 짧고 효과적인 치료 요법으로의 전환
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 결핵 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 질병 유형별(활동성 결핵, 잠재성 결핵)
- 치료법별(1차 치료제, 2차 치료제)
- 투여 경로별(경구, 비경구, 기타)
- 제형별(정제, 캡슐, 주사제, 기타)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 결핵 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제7장 유럽의 결핵 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 결핵 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 결핵 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 결핵 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향 및 발전
제13장 세계의 결핵 치료제 시장 : SWOT 분석
제14장 경쟁 구도
- AstraZeneca PLC
- Johnson & Johnson Services, Inc.
- Eli Lilly and Company
- Mylan Inc.
- Teva Pharmaceutical Industries Ltd
- Sanofi
- Novartis AG
- Sun Pharmaceutical Industries Ltd
- Pfizer Inc.
제15장 전략적 제안
제16장 기업 소개와 면책사항
HBR
The Global Tuberculosis Therapeutics Market was valued at USD 2.18 billion in 2024 and is projected to reach USD 2.94 billion by 2030, growing at a CAGR of 5.05%. Positioned as a crucial segment within infectious disease treatment, this market benefits from persistent global demand, especially due to the rising incidence of drug-resistant TB. Despite its historically low profit margins, the TB therapeutics space offers significant public health value and long-term commercial potential. Governments, health agencies, and pharmaceutical firms are increasingly prioritizing the development of innovative TB treatments, supported by consistent global case numbers and substantial funding from donors and public institutions. With next-generation drug development-particularly in second-line therapies-on the rise, companies that can balance cost-effectiveness, navigate regulatory landscapes, and build strategic collaborations are well-placed to secure a sustainable competitive edge.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 2.18 Billion |
| Market Size 2030 | USD 2.94 Billion |
| CAGR 2025-2030 | 5.05% |
| Fastest Growing Segment | First-line Therapy |
| Largest Market | Middle East & Africa |
Key Market Drivers
High Global Burden of Tuberculosis
The global tuberculosis (TB) burden remains a primary driver of market expansion. WHO data indicates that 10.8 million people contracted TB in 2023, up from 10.7 million in 2022, highlighting a rising trend. This sustained prevalence ensures ongoing demand for both first-line and second-line TB therapies, reinforcing the market's stability. For pharmaceutical companies, this represents a significant opportunity to scale drug portfolios and foster collaborations with public health organizations. The high incidence, particularly in regions with limited healthcare infrastructure, underscores the necessity for scalable treatment solutions, positioning the TB therapeutics market as a reliable avenue for both healthcare impact and commercial returns.
Key Market Challenges
Inadequate Funding and Limited Commercial Incentives for Drug Development
The concentration of TB cases in low- and middle-income countries often means that treatment relies on public funding and donor support rather than private investment. This results in limited profitability, discouraging pharmaceutical companies from prioritizing TB drug development. With constrained pricing models, complex regulatory pathways, and minimal patent protection, the return on investment for TB drugs is typically low. Further, the extended timelines of clinical trials and dependency on external funding inhibit innovation. Without enhanced incentives such as co-development frameworks or market guarantees, TB therapeutics are likely to lag behind other disease areas in terms of pharmaceutical innovation.
Key Market Trends
Shift Toward Shorter, More Effective Treatment Regimens
There is a growing emphasis on developing shorter, more tolerable TB treatment regimens to improve adherence and outcomes. Novel combinations, such as the 6-month BPaL regimen, are transforming the landscape by reducing the treatment burden compared to traditional 18-24-month protocols. Supported by WHO endorsements and donor-funded initiatives, these advancements are generating increased interest in next-generation therapies. Pharmaceutical companies capable of innovating in fixed-dose combinations and new drug mechanisms stand to benefit from this shift, as these regimens often command higher per-patient value due to better efficacy, reduced side effects, and enhanced patient compliance.
Key Market Players
- AstraZeneca PLC
- Johnson & Johnson Services, Inc.
- Eli Lilly and Company
- Mylan Inc.
- Teva Pharmaceutical Industries Ltd
- Sanofi
- Novartis AG
- Sun Pharmaceutical Industries Ltd
- Pfizer Inc.
Report Scope:
In this report, the Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Tuberculosis Therapeutics Market, By Disease Type:
Tuberculosis Therapeutics Market, By Therapy:
- First-Line Therapy
- Second-Line Therapy
Tuberculosis Therapeutics Market, By Route of Administration:
Tuberculosis Therapeutics Market, By Dosage Form:
- Tablets
- Capsules
- Injection
- Others
Tuberculosis Therapeutics Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Tuberculosis Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Tuberculosis Therapeutics Market.
Available Customizations:
Global Tuberculosis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Tuberculosis Therapeutics Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Disease Type (Active TB, Latent TB)
- 5.2.2. By Therapy (First-Line Therapy, Second-Line Therapy)
- 5.2.3. By Route of Administration (Oral, Parenteral, Others)
- 5.2.4. By Dosage Form (Tablets, Capsules, Injection, Others)
- 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
- 5.2.6. By Region
- 5.2.7. By Company (2024)
- 5.3. Market Map
6. North America Tuberculosis Therapeutics Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Disease Type
- 6.2.2. By Therapy
- 6.2.3. By Route of Administration
- 6.2.4. By Dosage Form
- 6.2.5. By Distribution Channel
- 6.2.6. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Tuberculosis Therapeutics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Disease Type
- 6.3.1.2.2. By Therapy
- 6.3.1.2.3. By Route of Administration
- 6.3.1.2.4. By Dosage Form
- 6.3.1.2.5. By Distribution Channel
- 6.3.2. Canada Tuberculosis Therapeutics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Disease Type
- 6.3.2.2.2. By Therapy
- 6.3.2.2.3. By Route of Administration
- 6.3.2.2.4. By Dosage Form
- 6.3.2.2.5. By Distribution Channel
- 6.3.3. Mexico Tuberculosis Therapeutics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Disease Type
- 6.3.3.2.2. By Therapy
- 6.3.3.2.3. By Route of Administration
- 6.3.3.2.4. By Dosage Form
- 6.3.3.2.5. By Distribution Channel
7. Europe Tuberculosis Therapeutics Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Disease Type
- 7.2.2. By Therapy
- 7.2.3. By Route of Administration
- 7.2.4. By Dosage Form
- 7.2.5. By Distribution Channel
- 7.2.6. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Tuberculosis Therapeutics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Disease Type
- 7.3.1.2.2. By Therapy
- 7.3.1.2.3. By Route of Administration
- 7.3.1.2.4. By Dosage Form
- 7.3.1.2.5. By Distribution Channel
- 7.3.2. United Kingdom Tuberculosis Therapeutics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Disease Type
- 7.3.2.2.2. By Therapy
- 7.3.2.2.3. By Route of Administration
- 7.3.2.2.4. By Dosage Form
- 7.3.2.2.5. By Distribution Channel
- 7.3.3. Italy Tuberculosis Therapeutics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Disease Type
- 7.3.3.2.2. By Therapy
- 7.3.3.2.3. By Route of Administration
- 7.3.3.2.4. By Dosage Form
- 7.3.3.2.5. By Distribution Channel
- 7.3.4. France Tuberculosis Therapeutics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Disease Type
- 7.3.4.2.2. By Therapy
- 7.3.4.2.3. By Route of Administration
- 7.3.4.2.4. By Dosage Form
- 7.3.4.2.5. By Distribution Channel
- 7.3.5. Spain Tuberculosis Therapeutics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Disease Type
- 7.3.5.2.2. By Therapy
- 7.3.5.2.3. By Route of Administration
- 7.3.5.2.4. By Dosage Form
- 7.3.5.2.5. By Distribution Channel
8. Asia-Pacific Tuberculosis Therapeutics Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Disease Type
- 8.2.2. By Therapy
- 8.2.3. By Route of Administration
- 8.2.4. By Dosage Form
- 8.2.5. By Distribution Channel
- 8.2.6. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Tuberculosis Therapeutics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Disease Type
- 8.3.1.2.2. By Therapy
- 8.3.1.2.3. By Route of Administration
- 8.3.1.2.4. By Dosage Form
- 8.3.1.2.5. By Distribution Channel
- 8.3.2. India Tuberculosis Therapeutics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Disease Type
- 8.3.2.2.2. By Therapy
- 8.3.2.2.3. By Route of Administration
- 8.3.2.2.4. By Dosage Form
- 8.3.2.2.5. By Distribution Channel
- 8.3.3. Japan Tuberculosis Therapeutics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Disease Type
- 8.3.3.2.2. By Therapy
- 8.3.3.2.3. By Route of Administration
- 8.3.3.2.4. By Dosage Form
- 8.3.3.2.5. By Distribution Channel
- 8.3.4. South Korea Tuberculosis Therapeutics Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Disease Type
- 8.3.4.2.2. By Therapy
- 8.3.4.2.3. By Route of Administration
- 8.3.4.2.4. By Dosage Form
- 8.3.4.2.5. By Distribution Channel
- 8.3.5. Australia Tuberculosis Therapeutics Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Disease Type
- 8.3.5.2.2. By Therapy
- 8.3.5.2.3. By Route of Administration
- 8.3.5.2.4. By Dosage Form
- 8.3.5.2.5. By Distribution Channel
9. South America Tuberculosis Therapeutics Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Disease Type
- 9.2.2. By Therapy
- 9.2.3. By Route of Administration
- 9.2.4. By Dosage Form
- 9.2.5. By Distribution Channel
- 9.2.6. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Tuberculosis Therapeutics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Disease Type
- 9.3.1.2.2. By Therapy
- 9.3.1.2.3. By Route of Administration
- 9.3.1.2.4. By Dosage Form
- 9.3.1.2.5. By Distribution Channel
- 9.3.2. Argentina Tuberculosis Therapeutics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Disease Type
- 9.3.2.2.2. By Therapy
- 9.3.2.2.3. By Route of Administration
- 9.3.2.2.4. By Dosage Form
- 9.3.2.2.5. By Distribution Channel
- 9.3.3. Colombia Tuberculosis Therapeutics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Disease Type
- 9.3.3.2.2. By Therapy
- 9.3.3.2.3. By Route of Administration
- 9.3.3.2.4. By Dosage Form
- 9.3.3.2.5. By Distribution Channel
10. Middle East and Africa Tuberculosis Therapeutics Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Disease Type
- 10.2.2. By Therapy
- 10.2.3. By Route of Administration
- 10.2.4. By Dosage Form
- 10.2.5. By Distribution Channel
- 10.2.6. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Tuberculosis Therapeutics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Disease Type
- 10.3.1.2.2. By Therapy
- 10.3.1.2.3. By Route of Administration
- 10.3.1.2.4. By Dosage Form
- 10.3.1.2.5. By Distribution Channel
- 10.3.2. Saudi Arabia Tuberculosis Therapeutics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Disease Type
- 10.3.2.2.2. By Therapy
- 10.3.2.2.3. By Route of Administration
- 10.3.2.2.4. By Dosage Form
- 10.3.2.2.5. By Distribution Channel
- 10.3.3. UAE Tuberculosis Therapeutics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Disease Type
- 10.3.3.2.2. By Therapy
- 10.3.3.2.3. By Route of Administration
- 10.3.3.2.4. By Dosage Form
- 10.3.3.2.5. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Tuberculosis Therapeutics Market: SWOT Analysis
14. Competitive Landscape
- 14.1. AstraZeneca PLC
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. Johnson & Johnson Services, Inc.
- 14.3. Eli Lilly and Company
- 14.4. Mylan Inc.
- 14.5. Teva Pharmaceutical Industries Ltd
- 14.6. Sanofi
- 14.7. Novartis AG
- 14.8. Sun Pharmaceutical Industries Ltd
- 14.9. Pfizer Inc.
15. Strategic Recommendations
16. About Us & Disclaimer
